Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.79 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.79 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.79 |
| ▸ | TNF | P01375 | 1/20 | 0.79 |
| ▸ | IL1B | P01584 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283184 | 1.00 | CRBN (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30001891 | 1.00 | CRBN (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL283314 | 1.00 | CRBN (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22737352 | 0.89 | CRBN (0.78) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25346884 | 0.88 | DDB1 (0.76) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL16768175 | 0.88 | DDB1 (0.63) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL15120730 | 0.88 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21996834 | 0.88 | CRBN (0.76) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL283684 | 0.88 | DDB1 (0.76) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25347071 | 0.88 | DDB1 (0.76) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354417-B2 | Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same | CELGENE CORPORATION (US) | 2013-01-15 | — | — | US | claimed |
| US-20110111396-A1 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS | SCHAFER PETER H | 2011-05-12 | — | — | US | claimed |
| EP-2232267-A1 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS | CELGENE CORPORATION (US) | 2010-09-29 | — | — | EP | claimed |
| US-20100016342-A9 | SOLID FORMS COMPRISING 3-(2,5-DIMETHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2010-01-21 | — | — | US | claimed |
| WO-2009042200-A9 | SOLID FORMS COMPRISING 3-(2,5-DIMETHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2009075795-A1 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS | CELGENE CORPORATION (US) | 2009-06-18 | — | — | WO | claimed |
| WO-2009042200-A1 | SOLID FORMS COMPRISING 3-(2,5-DIMETHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | claimed |
| US-20090082375-A1 | SOLID FORMS COMPRISING 3-(2,5-DIMETHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2009-03-26 | — | — | US | claimed |
| US-20250382240-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-3743069-B1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BIOVENTURES, LLC (US) | 2024-10-15 | — | — | US | disclosed |
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20090082375-A1 | SOLID FORMS COMPRISING 3-(2,5-DIMETHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, IL15, CXCR5 | CRBN 2228/4885DDB1 781/4885IKZF3 14/4885 |
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BCL2, BCL2L1, BCL2L2 | CRBN 263/4885DDB1 163/4885IKZF3 1486/4885 |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | FGF2, TNF, FGF1 | CRBN 2562/4885DDB1 2526/4885IKZF3 3719/4885 |
| US-20090082375-A1 | SOLID FORMS COMPRISING 3-(2,5-DIMETHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | SDHA, SDHB, TPMT | CRBN 1851/4885DDB1 1153/4885IKZF3 3562/4885 |
| US-20100016342-A9 | SOLID FORMS COMPRISING 3-(2,5-DIMETHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | SDHA, SDHB, TPMT | CRBN 1851/4885DDB1 1153/4885IKZF3 3562/4885 |
| US-20250382240-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | CRBN 1871/4885DDB1 1162/4885IKZF3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.